Harbor Capital Advisors Inc. Acquires New Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Harbor Capital Advisors Inc. purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 97,543 shares of the company’s stock, valued at approximately $2,438,000. Harbor Capital Advisors Inc. owned approximately 0.14% of Kiniksa Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Hhlr Advisors LTD. purchased a new position in shares of Kiniksa Pharmaceuticals in the 1st quarter worth approximately $61,868,000. Vanguard Group Inc. increased its position in shares of Kiniksa Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock valued at $58,833,000 after buying an additional 16,595 shares during the period. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals by 10.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after acquiring an additional 157,741 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in Kiniksa Pharmaceuticals by 8.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after buying an additional 49,000 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares of the company’s stock, valued at $3,226,805.01. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,692 shares of company stock valued at $2,950,315 in the last ninety days. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 4.4 %

Shares of Kiniksa Pharmaceuticals stock opened at $21.48 on Tuesday. The firm has a market cap of $1.53 billion, a PE ratio of -156.70 and a beta of 0.35. The stock has a 50 day moving average of $25.40 and a 200 day moving average of $22.53. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $14.12 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue was up 67.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.20) EPS. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KNSA shares. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Wedbush upped their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Evercore ISI raised their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average target price of $34.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.